↓ Skip to main content

Dove Medical Press

Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab

Overview of attention for article published in Breast cancer targets and therapy, April 2022
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (75th percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

news
1 news outlet

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
34 Mendeley
Title
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
Published in
Breast cancer targets and therapy, April 2022
DOI 10.2147/bctt.s293597
Pubmed ID
Authors

Nusayba A Bagegni, Andrew A Davis, Katherine K Clifton, Foluso O Ademuyiwa

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 34 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 34 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 4 12%
Student > Master 3 9%
Student > Ph. D. Student 3 9%
Student > Bachelor 2 6%
Other 2 6%
Other 4 12%
Unknown 16 47%
Readers by discipline Count As %
Medicine and Dentistry 8 24%
Biochemistry, Genetics and Molecular Biology 3 9%
Pharmacology, Toxicology and Pharmaceutical Science 1 3%
Sports and Recreations 1 3%
Unspecified 1 3%
Other 0 0%
Unknown 20 59%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 February 2023.
All research outputs
#4,840,893
of 25,392,582 outputs
Outputs from Breast cancer targets and therapy
#64
of 324 outputs
Outputs of similar age
#105,773
of 447,757 outputs
Outputs of similar age from Breast cancer targets and therapy
#4
of 8 outputs
Altmetric has tracked 25,392,582 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 324 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.0. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,757 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 4 of them.